Skip to main content
. 2022 Jul 14;140(2):112–120. doi: 10.1182/blood.2021014960

Table 2.

Reason for ibrutinib discontinuation

Reason for discontinuation Number of patients who discontinued Percentage among all IR patients who started IR, n = 352 Percentage among IR patients discontinuing treatment, n = 138
Progression or death 37 10.5 26.8
AE or complications 77 21.9 55.8
Withdrawal or other reason* 24 6.8 17.4
*

Other reasons: lost insurance (n = 2), missed visits or noncompliance (n = 5), moved to a new location or site (n = 3).